InvestorsHub Logo
Followers 12
Posts 489
Boards Moderated 0
Alias Born 08/03/2013

Re: KCRoyal2004 post# 19387

Friday, 03/06/2020 5:38:33 PM

Friday, March 06, 2020 5:38:33 PM

Post# of 27434
KC sorry I missed your post but good to know I wasn't the only one that picked up on this. It seems now that the company's best prospects for getting the device used in applications here in the US are now for Breakthrough Device designation for the removal of platelet-inhibiting drugs (ticagrelor, others) or for Emergency Use Authorization for the coronavirus. This as Dr. Chan as the acting CMO is probably putting his sole focus on these areas, and REFRESH and Hemodefend are now long term efforts that the new CMO will probably be tasked with getting back on track once they hire someone.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News